Quest Diagnostics has outpaced its healthcare peers over the past year, and analysts are maintaining a moderately positive outlook on its future performance.
The Oncodetect ® test expands the role of tumor-informed MRD in triple-negative breast cancer The Cancerguard ® test demonstrates improved...
1 Mid-Cap Stock to Consider Right Now and 2 Facing Headwinds
3 Cash-Producing Stocks We Approach with Caution
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive...
Amalgam Rx, Inc., Privia Health, and Exact Sciences Corp. highlight how coordinated, EHR-enabled patient outreach supported measurable screening impact at scale.
Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition...
Paul Tudor has bought a fresh position on tech giant Google and more.
3 Unpopular Stocks We Approach with Caution
3 Overrated Stocks That Concern Us